Merz Aesthetics

Merz Aesthetics is a prominent, family-owned pharmaceutical entity established in 1908, specializing in aesthetic medicine and botulinum toxin therapy. The company maintains a robust portfolio focused on three core business segments: aesthetic medicine, neurology, and over-the-counter preparations. By delivering innovative solutions to healthcare professionals and patients worldwide, the firm has solidified its position as a leader in minimally invasive aesthetic procedures and neurological disorder treatments.

The company’s product suite includes high-demand medical solutions such as Belotero, Radiesse, Ultherapy, Xeomin, and Contractubex. These offerings support diverse clinical needs, ranging from ultrasound skin lifting to specialized therapies for dementia. With a workforce of 1,000-5,000 employees, Merz Aesthetics manages complex operational requirements across its global footprint. The organization leverages its deep expertise in pharmaceutical development to maintain high standards of safety and efficacy in its therapeutic and aesthetic product lines.

Operating internationally, the company maintains a significant presence across Europe, the United States, Canada, Mexico, Brazil, and the Asia-Pacific region. The firm’s commitment to advancing healthcare outcomes is supported by its dedicated workforce. Meet Merz Aesthetics's team to learn about the leadership driving these global initiatives. With a revenue of $325.7M, the company continues to expand its market reach while adhering to its long-standing tradition of excellence in the pharmaceutical sector.